(Press-News.org) Using machine learning, researchers at the UC Davis MIND Institute have identified several patterns of maternal autoantibodies highly associated with the diagnosis and severity of autism.
Their study, published Jan. 22 in Molecular Psychiatry, specifically focused on maternal autoantibody-related autism spectrum disorder (MAR ASD), a condition accounting for around 20% of all autism cases.
"The implications from this study are tremendous," said Judy Van de Water, a professor of rheumatology, allergy and clinical immunology at UC Davis and the lead author of the study. "It's the first time that machine learning has been used to identify with 100% accuracy MAR ASD-specific patterns as potential biomarkers of ASD risk."
Autoantibodies are immune proteins that attack a person's own tissues. Previously, Van de Water found that a pregnant mother's autoantibodies can react with her growing fetus' brain and alter its development.
Machine learning identifies patterns indicating likelihood and severity of autism
The research team obtained plasma samples from mothers enrolled in the CHARGE study. They analyzed the samples from 450 mothers of children with autism and 342 mothers of typically developing children, also from CHARGE, to detect reactivity to eight different proteins that are abundant in fetal brain. They then used a machine learning algorithm to determine which autoantibody patterns were specifically associated with a diagnosis of ASD.
The researchers created and validated a test to identify ASD-specific maternal autoantibody patterns of reactivity against eight proteins highly expressed in the developing brain.
"The big deal about this particular study is that we created a new, very translatable test for future clinical use," said Van de Water. This simple maternal blood test uses an ELISA (Enzyme-Linked-ImmunoSorbent Assay) platform, which is very quick and accurate.
The machine learning program crunched roughly 10,000 patterns and identified three top patterns associated with MAR ASD: CRMP1+GDA, CRMP1+CRMP2 and NSE+STIP1.
"For example, if the mother has autoantibodies to CRIMP1 and GDA (the most common pattern), her odds of having a child with autism is 31 times greater than the general population, based on this current dataset. That's huge," said Van de Water. "There's very little out there that is going to give you that type of risk assessment."
Researchers also found that reactivity to CRMP1 in any of the top patterns significantly increases the odds of a child having more severe autism.
Future implications
Van de Water notes that with these maternal biomarkers, there are possibilities for very early diagnosis of MAR autism and more effective behavioral intervention. The study opens the door for more research on potential pre-conception testing, particularly useful for high-risk women older than 35 or who have already given birth to a child with autism.
"We can envision that a woman could have a blood test for these antibodies prior to getting pregnant. If she had them, she'd know she would be at very high risk of having a child with autism. If not, she has a 43% lower chance of having a child with autism as MAR autism is ruled out," Van de Water said.
Van de Water is currently researching the pathologic effects of maternal autoantibodies using animal models. "We will also use these animal models to develop therapeutic strategies to block the maternal autoantibodies from the fetus," said Van de Water.
"This study is a big deal in terms of early risk assessment for autism, and we're hoping that this technology will become something that will be clinically useful in the future."
INFORMATION:
First author on the study is Alexandra Ramirez-Celis, with co-authors Joseph Schauer and Miriam Nuño from UC Davis, and Nima Aghaeepour and Martin Becker from Stanford University.
Funding for the study was provided by the NIEHS Center for Children's Environmental Health and Environmental Protection Agency (EPA) grants (2P01ES011269-11, 83543201), the NIEHS-funded CHARGE study (R01ES015359), the NICHD-funded IDDRC 054 (U54HD079125), and Consejo Nacional de Ciencia y Tecnologia (CONACYT- UC MEXUS) Doctoral Fellowships, and NIH grant R35 GM138353.
Irvine, Calif., Jan. 25, 2021 -- Scientists at the University of California, Irvine and NASA's Jet Propulsion Laboratory have for the first time quantified how warming coastal waters are impacting individual glaciers in Greenland's fjords. Their work is the subject of a study published recently in Science Advances.
Working under the auspices of the Oceans Melting Greenland mission for the past five years, the researchers used ships and aircraft to survey 226 glaciers in all sectors of one of Earth's largest islands. They found that 74 glaciers situated in deep, steep-walled valleys accounted for nearly half of Greenland's total ice loss between 1992 and 2017.
Such fjord-bound glaciers were discovered to be the ...
Epilepsy, a neurological disease that causes recurring seizures with a wide array of effects, impacts approximately 50 million people across the world. This condition has been recognized for a long time -- written records of epileptic symptoms date all the way back to 4000 B.C.E. But despite this long history of knowledge and treatment, the exact processes that occur in the brain during a seizure remain elusive.
Scientists have observed distinctive patterns in the electrical activity of neuron groups in healthy brains. Networks of neurons move through states of similar behavior (synchronization) and dissimilar behavior (desynchronization) ...
A new study demonstrates that antibodies generated by the novel coronavirus react to other strains of coronavirus and vice versa, according to research published today by scientists from Oregon Health & Science University.
However, antibodies generated by the SARS outbreak of 2003 had only limited effectiveness in neutralizing the SARS-CoV-2 virus. Antibodies are blood proteins that are made by the immune system to protect against infection, in this case by a coronavirus.
The study published today in the journal Cell Reports.
"Our finding has some important implications concerning immunity toward different strains of coronavirus infections, ...
Astrocytes are the most abundant type of cells within the central nervous system (CNS), but they remain poorly characterized. Researchers have long assumed that astrocytes' primary function is to provide nutrients and support for the brain's more closely scrutinized nerve cells; over the years, however, increasing evidence has shown that astrocytes can also actively promote neurodegeneration, inflammation, and neurological diseases. Now, a team led by researchers from Brigham and Women's Hospital, has shown that a specific astrocyte sub-population can do the opposite, instead serving a protective, anti-inflammatory function within the brain based on signals regulated by the bacteria that reside in ...
-Data demonstrate ADG2 binds to all known variants of SARS-CoV-2 and is not impacted by known circulating resistance mutations-
-Company expects to begin clinical studies for a half-life extended version of ADG2 for the treatment and prevention of COVID-19 in early 2021-
Waltham, MA - January 25, 2021- Adagio Therapeutics, Inc., a biotechnology company developing best-in-class antibodies to broadly neutralize coronaviruses, today published in vitro and in vivo data in Science on its lead antibody candidate, ADG2, which demonstrated similar or higher potency against SARS-CoV-2 compared to other monoclonal antibodies (mAbs) in clinical development and strong binding to all known ...
Working in preclinical models, researchers report that plitidepsin, a drug with limited clinical approval for the treatment of multiple myeloma, is more potent against SARS-CoV-2 than remdesivir, an antiviral that received FDA emergency use authorization for the treatment of COVID-19 in 2020. The results suggest plitidepsin should be further evaluated as a COVID-19 therapy, the authors say; because it targets a host protein rather than a viral protein, if treatment proves successful in humans, the SARS-CoV-2 virus won't be easily able to gain resistance ...
A new approach to mapping viral mutations that "escape" leading clinical antibodies has revealed mutations in the SARS-CoV-2 virus that allow it to evade treatments, including a single amino-acid mutation that fully escapes Regeneron's antibody cocktail. These maps, say the authors, demonstrate that prior characterization of escape mutations was incomplete. They will also help to enable immediate interpretation of the effects of the mutations cataloged by viral genomic surveillance, say the authors. Several antibodies are in use or under development as therapies to treat COVID-19. As new SARS-CoV-2 variants emerge, it ...
Researchers have engineered an antibody that neutralizes SARS-CoV-2 with a potency that "rivals" current lead SARS-CoV-2 clinical neutralizing antibodies, and that also broadly neutralizes a range of clade 1 sarbecoviruses. Their antibody, ADG-2, studied in mice, represents a "promising candidate" for the prevention and treatment of not only COVID-19, they say, but also of future respiratory diseases caused by SARS-related coronaviruses. Although two vaccines and two monoclonal antibody (mAb) therapies have been authorized for emergency use by the FDA, it is unknown whether these vaccines and treatments will provide broad protection against new emerging SARS-CoV-2 strains that originate in humans or animal reservoirs; this is partly ...
During the first wave of the COVID-19 pandemic, nearly one in four families responded that they would be unlikely to bring their child to the Emergency Department if they had an emergency condition, according to a survey from Ann & Robert H. Lurie Children's Hospital of Chicago published in the journal Academic Emergency Medicine. Greater hesitancy to seek emergency care was found in families living in under-resourced communities, those who rely on public insurance and in families who are Black, Latinx or Asian.
"We observed greater hesitancy to use the Emergency Department among more vulnerable demographic groups who historically showed high utilization of emergency care for their children," ...
Cancer is the second leading cause of death in the world. The number of deaths and incidences is increasing each year. The metal-based anticancer drugs were used clinically worldwide, but suffer from poor selectivity, serious side effects and drug resistance. Tumor-targeting drug development is the basis for precise cancer treatment.
Recently, Professor Hongke Liu of Nanjing Normal University, Professor Jing Zhao and Academician Zijian Guo of Nanjing University have made breakthrough achievements in anticancer drug development. They proposed a "bio-orthogonally catalyzed lethality" (BCL) strategy ...
